Related Experiment Videos
Hrad17 expression in thymoma.
Hidefumi Sasaki1, Yoshihiro Kobayashi, Haruhiro Yukiue
1Department of Surgery II, Nagoya City University Medical School, Nagoya, Japan.
The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai Zasshi
|April 15, 2003
Summary
The human homolog of rad17 (Hrad17) gene is highly expressed in invasive thymoma. This finding suggests Hrad17 may play a role in thymoma progression and could be a potential biomarker for invasive thymoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Genomic instability, resulting from checkpoint control loss, is linked to tumor progression.
- The human homolog of the Schizosaccharomyces pombe checkpoint gene rad17 (Hrad17) is a potential player in cancer development.
- This study investigates Hrad17 expression in thymoma, particularly invasive types.
Purpose of the Study:
- To identify and isolate the Hrad17 gene.
- To determine Hrad17 expression levels in thymoma tissues.
- To assess the correlation between Hrad17 expression and clinicopathological features of thymoma.
Main Methods:
- Palindromic polymerase chain reaction-driven complementary DNA differential display was used to identify Hrad17.
- Reverse transcription-polymerase chain reaction (RT-PCR) with LightCycler quantified Hrad17 mRNA in 38 thymomas and 10 normal thymus samples.
- Immunohistochemistry was employed to assess Hrad17 protein expression.
Main Results:
- Hrad17 transcripts were significantly elevated in all 38 thymoma samples compared to normal thymus (p < 0.0001).
- Hrad17 mRNA levels were significantly higher in invasive thymomas (Stage II-IV) than in Stage I thymomas (p = 0.0168).
- Immunohistochemistry confirmed high Hrad17 protein expression in invasive thymoma tissue, but not in normal thymus.
Conclusions:
- Hrad17 is highly expressed in invasive thymoma.
- Elevated Hrad17 expression correlates with advanced stage invasive thymoma.
- Hrad17 may serve as a potential biomarker for invasive thymoma.